North America Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity
North America influenza treatment market is expected to grow by 2.3% annually in the forecast period and reach $569.8 million by 2030 driven by rising incidences of influenza, growing awareness and need for new drugs and treatment in the region.
Highlighted with 23 tables and 40 figures, this 91-page report “North America Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Highlighted with 23 tables and 40 figures, this 91-page report “North America Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Fiver Forces
Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Oseltamivir Phosphate
- Baloxavir Marboxil
- Peramivir
- Zanamivir
- Other Drugs
- Influenza A
- Influenza B
- Influenza C
- Oral Administration
- Other Administration Routes
- Retail Pharmacy
- Hospital Pharmacy
- Clinics
- Online Stores
- U.S.
- Canada
- Mexico
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 INTRODUCTION
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF NORTH AMERICA MARKET BY PRODUCT TYPE
3.1 Market Overview by Product Type
3.2 Oseltamivir Phosphate
3.3 Baloxavir Marboxil
3.4 Peramivir
3.5 Zanamivir
3.6 Other Drugs
4 SEGMENTATION OF NORTH AMERICA MARKET BY INFLUENZA TYPE
4.1 Market Overview by Influenza Type
4.2 Influenza A
4.3 Influenza B
4.4 Influenza C
5 SEGMENTATION OF NORTH AMERICA MARKET BY ADMINISTRATION ROUTE
5.1 Market Overview by Administration Route
5.2 Oral Administration
5.3 Other Administration Routes
6 SEGMENTATION OF NORTH AMERICA MARKET BY DISTRIBUTION CHANNEL
6.1 Market Overview by Distribution Channel
6.2 Retail Pharmacy
6.3 Hospital Pharmacy
6.4 Clinics
6.5 Online Stores
7 NORTH AMERICA MARKET 2019-2030 BY COUNTRY
7.1 Overview of North America Market
7.2 U.S.
7.3 Canada
7.4 Mexico
8 COMPETITIVE LANDSCAPE
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
9 INVESTING IN NORTH AMERICA MARKET: RISK ASSESSMENT AND MANAGEMENT
9.1 Risk Evaluation of North America Market
9.2 Critical Success Factors (CSFs)
Related Reports and Products
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF NORTH AMERICA MARKET BY PRODUCT TYPE
3.1 Market Overview by Product Type
3.2 Oseltamivir Phosphate
3.3 Baloxavir Marboxil
3.4 Peramivir
3.5 Zanamivir
3.6 Other Drugs
4 SEGMENTATION OF NORTH AMERICA MARKET BY INFLUENZA TYPE
4.1 Market Overview by Influenza Type
4.2 Influenza A
4.3 Influenza B
4.4 Influenza C
5 SEGMENTATION OF NORTH AMERICA MARKET BY ADMINISTRATION ROUTE
5.1 Market Overview by Administration Route
5.2 Oral Administration
5.3 Other Administration Routes
6 SEGMENTATION OF NORTH AMERICA MARKET BY DISTRIBUTION CHANNEL
6.1 Market Overview by Distribution Channel
6.2 Retail Pharmacy
6.3 Hospital Pharmacy
6.4 Clinics
6.5 Online Stores
7 NORTH AMERICA MARKET 2019-2030 BY COUNTRY
7.1 Overview of North America Market
7.2 U.S.
7.3 Canada
7.4 Mexico
8 COMPETITIVE LANDSCAPE
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
9 INVESTING IN NORTH AMERICA MARKET: RISK ASSESSMENT AND MANAGEMENT
9.1 Risk Evaluation of North America Market
9.2 Critical Success Factors (CSFs)
Related Reports and Products
LIST OF TABLES
Table 1. Snapshot of North America Influenza Treatment Market, 2019-2030
Table 2. Main Product Trends and Market Opportunities in North America Influenza Treatment Market
Table 3. North America Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 4. North America Influenza Treatment Market by Influenza Type, 2019-2030, $ mn
Table 5. North America Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 6. North America Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 7. North America Influenza Treatment Market by Country, 2019-2030, $ mn
Table 8. U.S. Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 9. U.S. Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 10. U.S. Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 11. Canada Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 12. Canada Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 13. Canada Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 14. Mexico Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 15. Mexico Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 16. Mexico Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 17. AstraZeneca Plc: Company Snapshot
Table 18. AstraZeneca Plc: Business Segmentation
Table 19. AstraZeneca Plc: Product Portfolio
Table 20. AstraZeneca Plc: Revenue, 2016-2018, $ mn
Table 21. AstraZeneca Plc: Recent Developments
Table 22. Risk Evaluation for Investing in North America Market, 2019-2030
Table 23. Critical Success Factors and Key Takeaways
Table 1. Snapshot of North America Influenza Treatment Market, 2019-2030
Table 2. Main Product Trends and Market Opportunities in North America Influenza Treatment Market
Table 3. North America Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 4. North America Influenza Treatment Market by Influenza Type, 2019-2030, $ mn
Table 5. North America Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 6. North America Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 7. North America Influenza Treatment Market by Country, 2019-2030, $ mn
Table 8. U.S. Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 9. U.S. Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 10. U.S. Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 11. Canada Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 12. Canada Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 13. Canada Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 14. Mexico Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 15. Mexico Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 16. Mexico Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 17. AstraZeneca Plc: Company Snapshot
Table 18. AstraZeneca Plc: Business Segmentation
Table 19. AstraZeneca Plc: Product Portfolio
Table 20. AstraZeneca Plc: Revenue, 2016-2018, $ mn
Table 21. AstraZeneca Plc: Recent Developments
Table 22. Risk Evaluation for Investing in North America Market, 2019-2030
Table 23. Critical Success Factors and Key Takeaways
LIST OF FIGURES
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. North America Influenza Treatment Market, 2019-2030, $ mn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of North America Influenza Treatment Market
Figure 8. GDP per capita in the World, 1960-2018, $ thousand
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million
Figure 10. Primary Restraints and Impact Factors of North America Influenza Treatment Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of North America Influenza Treatment Market
Figure 13. Breakdown of North America Influenza Treatment Market by Product Type, 2019-2030, % of Revenue
Figure 14. North America Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%)
Figure 15. North America Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn
Figure 16. North America Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn
Figure 17. North America Influenza Treatment Market: Peramivir, 2019-2030, $ mn
Figure 18. North America Influenza Treatment Market: Zanamivir, 2019-2030, $ mn
Figure 19. North America Influenza Treatment Market: Other Drugs, 2019-2030, $ mn
Figure 20. Breakdown of North America Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue
Figure 21. North America Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%)
Figure 22. North America Influenza Treatment Market: Influenza A, 2019-2030, $ mn
Figure 23. North America Influenza Treatment Market: Influenza B, 2019-2030, $ mn
Figure 24. North America Influenza Treatment Market: Influenza C, 2019-2030, $ mn
Figure 25. Breakdown of North America Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue
Figure 26. North America Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%)
Figure 27. North America Influenza Treatment Market: Oral Administration, 2019-2030, $ mn
Figure 28. North America Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn
Figure 29. Breakdown of North America Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue
Figure 30. North America Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%)
Figure 31. North America Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn
Figure 32. North America Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn
Figure 33. North America Influenza Treatment Market: Clinics, 2019-2030, $ mn
Figure 34. North America Influenza Treatment Market: Online Stores, 2019-2030, $ mn
Figure 35. Breakdown of North America Influenza Treatment Market by Country, 2019 and 2030, % of Revenue
Figure 36. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 37. U.S. Influenza Treatment Market, 2019-2030, $ mn
Figure 38. Canada Influenza Treatment Market, 2019-2030, $ mn
Figure 39. Influenza Treatment Market in Mexico, 2015-2030, $ mn
Figure 40. Growth Stage of North America Influenza Treatment Industry over the Forecast Period
COMPANIES MENTIONED
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. North America Influenza Treatment Market, 2019-2030, $ mn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of North America Influenza Treatment Market
Figure 8. GDP per capita in the World, 1960-2018, $ thousand
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million
Figure 10. Primary Restraints and Impact Factors of North America Influenza Treatment Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of North America Influenza Treatment Market
Figure 13. Breakdown of North America Influenza Treatment Market by Product Type, 2019-2030, % of Revenue
Figure 14. North America Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%)
Figure 15. North America Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn
Figure 16. North America Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn
Figure 17. North America Influenza Treatment Market: Peramivir, 2019-2030, $ mn
Figure 18. North America Influenza Treatment Market: Zanamivir, 2019-2030, $ mn
Figure 19. North America Influenza Treatment Market: Other Drugs, 2019-2030, $ mn
Figure 20. Breakdown of North America Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue
Figure 21. North America Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%)
Figure 22. North America Influenza Treatment Market: Influenza A, 2019-2030, $ mn
Figure 23. North America Influenza Treatment Market: Influenza B, 2019-2030, $ mn
Figure 24. North America Influenza Treatment Market: Influenza C, 2019-2030, $ mn
Figure 25. Breakdown of North America Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue
Figure 26. North America Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%)
Figure 27. North America Influenza Treatment Market: Oral Administration, 2019-2030, $ mn
Figure 28. North America Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn
Figure 29. Breakdown of North America Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue
Figure 30. North America Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%)
Figure 31. North America Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn
Figure 32. North America Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn
Figure 33. North America Influenza Treatment Market: Clinics, 2019-2030, $ mn
Figure 34. North America Influenza Treatment Market: Online Stores, 2019-2030, $ mn
Figure 35. Breakdown of North America Influenza Treatment Market by Country, 2019 and 2030, % of Revenue
Figure 36. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 37. U.S. Influenza Treatment Market, 2019-2030, $ mn
Figure 38. Canada Influenza Treatment Market, 2019-2030, $ mn
Figure 39. Influenza Treatment Market in Mexico, 2015-2030, $ mn
Figure 40. Growth Stage of North America Influenza Treatment Industry over the Forecast Period
COMPANIES MENTIONED
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
